To provide for a limitation on availability of funds for Related Agency and Food and Drug Administration, Buildings and Facilities for fiscal year 2024.

Bill 118 hr 2296, also known as the "Limitation on Availability of Funds for FDA Buildings and Facilities Act," aims to place restrictions on the availability of funds for the Food and Drug Administration (FDA) and related agency buildings and facilities for the fiscal year 2024.

The bill seeks to limit the amount of money that can be allocated towards the construction, renovation, or maintenance of FDA and related agency buildings and facilities. This limitation is intended to ensure that taxpayer dollars are being used efficiently and effectively, and to prevent any unnecessary or excessive spending on these projects.

By placing restrictions on the availability of funds for FDA buildings and facilities, the bill aims to promote fiscal responsibility and accountability within the agency. It also aims to prioritize funding for other important programs and initiatives within the FDA that may have a more direct impact on public health and safety. Overall, Bill 118 hr 2296 seeks to ensure that taxpayer dollars are being used wisely and responsibly when it comes to funding FDA buildings and facilities, and to promote transparency and accountability within the agency.